专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2014094948A Insulinotropic peptide derivative in which its n-terminal amino acid is modified 审中-公开
标题翻译：其N-末端氨基酸的胰岛素衍生物被修饰
公开(公告)号：JP2014094948A
公开(公告)日：2014-05-22
申请号：JP2013264258
申请日：2013-12-20
申请人： Hanmi Science Co Ltd , ハンミサイエンスカンパニーリミテッドHanmi Science Co.,Ltd.
发明人： JUNG SUNG YOUB , LIM CHANG KI , SONG DAE HAE , BAE SUNG MIN , KIM YON FUN , KWON SE CHANG , LEE GWAN SUN
IPC分类号： C07K14/46 , A61K38/28 , A61P3/10
CPC分类号： C07K14/46 , A61K38/26 , C07K14/57563 , C07K14/605
摘要： PROBLEM TO BE SOLVED: To provide an insulinotropic peptide derivative which is high blood stability and insulinotropic activity.SOLUTION: Insulinotropic peptide derivative is obtained by substituting 4-imidazoacetyl for an N-terminal histidine residue of native insulinotropic peptide. The native insulinotropic peptide is selected from exendin-4, exendin-3 and derivative thereof. The insulinotropic peptide derivative exhibits therapeutic effect, which are not observed in native and other insulinotropic peptide analog. The insulinotropic peptide derivative and the pharmaceutical composition comprising the same can be effectively provided for the treatment of diabetes.
摘要翻译：要解决的问题：提供高血液稳定性和促胰岛素活性的促胰岛素肽衍生物。解决方案：通过用4-咪唑乙酰替代天然促胰岛素肽的N-末端组氨酸残基获得胰岛素性肽衍生物。天然促胰岛素肽选自毒蜥外泌肽-4，毒蜥外泌肽-3及其衍生物。促胰岛素肽衍生物表现出治疗效果，其在天然和其他促胰岛素肽类似物中未观察到。促胰岛素肽衍生物和包含其的药物组合物可以有效地用于治疗糖尿病。

2. 发明专利

JP2013010779A Insulinotropic peptide derivative wherein its n-terminal amino acid is modified 有权
标题翻译：胰岛素衍生物其N-末端氨基酸被修饰
公开(公告)号：JP2013010779A
公开(公告)日：2013-01-17
申请号：JP2012193520
申请日：2012-09-03
申请人： Hanmi Science Co Ltd , ハンミサイエンスカンパニーリミテッドHanmi Science Co.,Ltd.
发明人： JUNG SUNG YOUB , LIM CHANG KI , SONG DAE HAE , BAE SUNG MIN , KIM YOUNG HOON , KWON SE CHANG , LEE GWAN SUN
IPC分类号： C07K14/46 , A61K38/04 , A61P3/10
CPC分类号： C07K14/46 , A61K38/26 , C07K14/57563 , C07K14/605
摘要： PROBLEM TO BE SOLVED: To provide an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to provide a pharmaceutical composition comprising the same.SOLUTION: In the insulinotropic peptide derivative, N-terminal histidine residue of a native insulinotropic peptide is substituted by N-dimethyl-histidyl. The insulinotropic peptide derivatives exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same can be used for the effective treatment of diabetes.
摘要翻译：待解决的问题：提供具有高活性的N-末端氨基酸修饰的促胰岛素肽，并提供包含其的药物组合物。解决方案：在促胰岛素肽衍生物中，天然促胰岛素肽的N-末端组氨酸残基被N-二甲基 - 组氨酰取代。促胰岛素肽衍生物表现出治疗效果，其在天然和其他促胰岛素肽类似物中未观察到。因此，促胰岛素肽衍生物及其组合物可用于糖尿病的有效治疗。版权所有（C）2013，JPO＆INPIT

3. 发明专利

JP2014110816A METHOD FOR MASS PRODUCTION OF IMMUNOGLOBULIN Fc REGION HAVING INITIAL METHIONINE RESIDUES DELETED THEREFROM 审中-公开
标题翻译：用于大量生产已经被除去的初始甲硫氨酸残基的免疫球蛋白Fc区的方法
公开(公告)号：JP2014110816A
公开(公告)日：2014-06-19
申请号：JP2014063351
申请日：2014-03-26
申请人： Hanmi Science Co Ltd , ハンミ・サイエンス・カンパニー・リミテッドHanmi Science Co., Ltd.
发明人： JUNG SUNG YOUB , KIM JIN SUN , SHIN JIN HWAN , KWON SE-CHANG , LEE GWAN-SUN , SONG DAE HAE
IPC分类号： C12P21/08 , C12N15/09
CPC分类号： C07K16/00 , A61K47/6811 , A61K47/6835 , C07K2317/41 , C07K2317/52
摘要： PROBLEM TO BE SOLVED: To provide a method for the mass production of an immunoglobulin Fc region, free of initial methionine residues.SOLUTION: Disclosed is a method for the mass production of a monomeric or dimeric immunoglobulin Fc region, free of initial methionine residues, using a recombinant expression vector comprising a nucleotide sequence coding for a recombinant immunoglobulin Fc region comprising an immunoglobulin hinge Fc region linked at the N-terminus thereof to an immunoglobulin Fc region via a peptide bond. Thus the monomeric or dimeric immunoglobulin Fc region, free of the initial methionine residues, is mass-produced.
摘要翻译：要解决的问题：提供大量生产不含初始甲硫氨酸残基的免疫球蛋白Fc区的方法。解决方案：公开了大量生产没有初始甲硫氨酸残基的单体或二聚体免疫球蛋白Fc区的方法，使用包含编码重组免疫球蛋白Fc区的核苷酸序列的重组表达载体，所述重组免疫球蛋白Fc区包含通过肽键与N末端连接的免疫球蛋白铰链Fc区与免疫球蛋白Fc区。因此，大量生产不含初始甲硫氨酸残基的单体或二聚体免疫球蛋白Fc区。

4. 发明专利

JP2013014598A Insulinotropic peptide derivative wherein its n-terminal amino acid is modified 有权
标题翻译：胰岛素衍生物其N-末端氨基酸被修饰
公开(公告)号：JP2013014598A
公开(公告)日：2013-01-24
申请号：JP2012193521
申请日：2012-09-03
申请人： Hanmi Science Co Ltd , ハンミサイエンスカンパニーリミテッドHanmi Science Co.,Ltd.
发明人： JUNG SUNG YOUB , LIM CHANG KI , SONG DAE HAE , BAE SUNG MIN , KIM YOUNG HOON , KWON SE CHANG , LEE GWAN SUN
IPC分类号： C07K14/46 , A61K38/00 , A61P3/10
CPC分类号： C07K14/46 , A61K38/26 , C07K14/57563 , C07K14/605
摘要： PROBLEM TO BE SOLVED: To provide an N-terminal amino acid-modified insulinotropic peptide having a high activity, and to provide a pharmaceutical composition comprising the same.SOLUTION: An insulinotropic peptide derivative, wherein N-terminal histidine residue of native insulinotropic peptide is replaced with beta-hydroxy imidazopropionyl. The insulinotropic peptide derivatives exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs.
摘要翻译：待解决的问题：提供具有高活性的N-末端氨基酸修饰的促胰岛素肽，并提供包含其的药物组合物。解决方案：促胰岛素肽衍生物，其中天然促胰岛素肽的N-末端组氨酸残基被β-羟基咪唑丙酰基替代。促胰岛素肽衍生物表现出治疗效果，其在天然和其他促胰岛素肽类似物中未观察到。版权所有（C）2013，JPO＆INPIT

5. 发明专利

JP2012224635A PHARMACEUTICAL COMPOSITION INCLUDING IMMUNOGLOBULIN Fc REGION AS CARRIER 审中-公开
标题翻译：药物组合物，包括作为载体的免疫球蛋白Fc区
公开(公告)号：JP2012224635A
公开(公告)日：2012-11-15
申请号：JP2012166208
申请日：2012-07-26
申请人： Hanmi Science Co Ltd , ハンミサイエンスカンパニーリミテッド
发明人： KIM YOUNG MIN , SONG DAE HAE , JUNG SUNG YOUB , KIM CHAN FAN , CHOI IN YOUNG , KWON SE CHANG , LEE GWAN SUN
IPC分类号： A61K39/395 , A61K47/42 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/27 , A61K38/43 , A61K39/00 , A61K47/34 , A61K47/48 , C07K16/00 , C07K16/42 , C07K19/00 , C12N15/70
CPC分类号： A61K47/68 , A61K47/48369 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： PROBLEM TO BE SOLVED: To provide novel application of an immunoglobulin Fc region, more specifically, a pharmaceutical composition including the immunoglobulin Fc region as a carrier.SOLUTION: The pharmaceutical composition including the immunoglobulin Fc region as a carrier of a drug greatly increases a half-life of the coupled drug in blood while maintaining comparatively high in-vivo activity of the coupled drug. When the drug is a polypeptide drug, risk of immunoreactivity induction is reduced in comparison with a fusion protein of the immunoglobulin Fc region and a target protein. Consequently, application useful for development of long-acting pharmaceutical preparations of various polypeptide drugs is provided.
摘要翻译：要解决的问题：提供免疫球蛋白Fc区的更新应用，更具体地，包括作为载体的免疫球蛋白Fc区的药物组合物。解决方案：包含作为药物载体的免疫球蛋白Fc区域的药物组合物大大增加血液中偶联药物的半衰期，同时保持联合药物的较高的体内活性。当药物是多肽药物时，与免疫球蛋白Fc区域和靶蛋白质的融合蛋白相比，免疫反应性诱导的风险降低。因此，提供了用于开发各种多肽药物的长效药物制剂的应用。版权所有（C）2013，JPO＆INPIT

6. 发明专利

AR108767A2 UNA COMPOSICIÓN NO TERAPÉUTICA PARA SUPRIMIR LA INGESTA DE ALIMENTOS O REDUCIR LA GRASA CORPORAL 未知
公开(公告)号：AR108767A2
公开(公告)日：2018-09-26
申请号：ARP170101541
申请日：2017-06-06
申请人： HANMI SCIENCE CO LTD
发明人： LEE GWAN SUN , KWON SE CHANG , JUNG SUNG YOUB , KANG EUN HAE , PARK YOUNG JIN , KIM MIN YOUNG , SONG DAE HAE
IPC分类号： A61K38/16 , A61K39/39 , A61P3/04
摘要： Reivindicación 1: Una composición para el tratamiento de las enfermedades relacionadas con la obesidad las cuales se seleccionan del grupo que consiste en hiperlipidemia, reflujo gastroesofágico relacionado con la. obesidad, esteatohepatitis e hipercolesterolemia, caracterizada porque comprende un conjugado de péptido insulinotrópico en el cual un péptido insulinotrópico está unido a una región Fc de la inmunoglobulina, mediante un enlazador no peptidílico, seleccionado del grupo que consiste en SMCC (succinimidil-4-(N-maleimido-metil)ciclohexan-1-carboxilato), SFB (succinimidil-4-formilbenzoato), polietilenglicol, polipropilenglicol, polivinilpirrolidona, copolímeros de etilenglicol y propilenglicol, polioles polioxietilados, alcohol polivinílico, polisacáridos, dextrano, etiléter polivinílico, polímeros biodegradables, tales como PLA (polylactic acid, ácido poliláctico) y PLGA (polylactic-glycolic acid, ácido poliláctico-glicólico), polímeros lipídicos, quitinas, ácido hialurónico y combinaciones de los mismos; y en la cual el péptido insulinotrópico se selecciona del grupo que consiste en: b-hidroxi imidazopropionil-exendina-4, en la que el grupo amino con extremo N-terminal de exendina-4 está sustituido con un grupo hidroxilo, b-carboxi imidazopropionil-exendina-4, en la que el grupo amino con extremo N-terminal de exendina-4 está sustituido con un grupo carboxilo, dimetil-histidil-exendina-4, en la que el grupo amino con extremo N-terminal de exendina-4 está modificado con dos grupos metilo e imidazo-acetil-exendina-4, en la que el carbono alfa del residuo de histidina con extremo N-terminal de exendina-4 ha sido eliminado.

7. 发明专利

PL2552474T3 Koniugat insuliny z fragmentem immunoglobuliny 未知
公开(公告)号：PL2552474T3
公开(公告)日：2017-08-31
申请号：PL11763093
申请日：2011-04-04
申请人： HANMI SCIENCE CO LTD
发明人： SONG DAE HAE , SHIN JAE HEE , PARK YOUNG JIN , IM DAE SEONG , BAE SUNG MIN , KWON SE CHANG
IPC分类号： A61K38/28 , A61K9/20 , A61K47/34 , A61K47/40 , A61K47/50 , C07K14/62

8. 发明专利

LT2552474T INSULINO KONJUGATAS SU IMUNOGLOBULINO FRAGMENTU 未知
公开(公告)号：LT2552474T
公开(公告)日：2017-06-12
申请号：LT11763093
申请日：2011-04-04
申请人： HANMI SCIENCE CO LTD
发明人： SONG DAE HAE , SHIN JAE HEE , PARK YOUNG JIN , IM DAE SEONG , BAE SUNG MIN , KWON SE CHANG
IPC分类号： A61K38/28 , A61K9/20 , A61K47/34 , A61K47/40 , A61K47/50 , C07K14/62

9. 发明专利

HRP20161055T1 POSTUPAK PROIZVODNJE KONJUGATA SPECIFIČNOG ZA MJESTO OD FIZIOLOŠKI DJELOTVORNOG POLIPEPTIDA 未知
公开(公告)号：HRP20161055T1
公开(公告)日：2016-11-04
申请号：HRP20161055
申请日：2016-08-21
申请人： HANMI SCIENCE CO LTD
发明人： SONG DAE HAE , SHIN JAE HEE , LEE JAE MIN , PARK YOUNG KYUNG , KWON SE CHANG , LEE GWAN SUN
IPC分类号： C07K1/14 , C07K1/10 , C07K1/18

10. 发明专利

NZ595848A Method for preparing a site-specific physiologically active polypeptide conjugate 未知
公开(公告)号：NZ595848A
公开(公告)日：2014-04-30
申请号：NZ59584810
申请日：2010-03-18
申请人： HANMI SCIENCE CO LTD
发明人： SONG DAE HAE , SHIN JAE HEE , LEE JAE MIN , PARK YOUNG KYUNG , KWON SE CHANG , LEE GWAN SUN
IPC分类号： C07K1/14 , C07K1/10 , C07K1/18
摘要： 595848 Disclosed is a method for preparing a site-specific physiologically active polypeptide conjugate, comprising the steps of: i) determining a kind and amount of an alcohol and a pH range where desired positional isomers exist more than undesired positional isomers by identifying a ratio of the desired and undesired positional isomers of a conjugate of a physiologically active polypeptide and a non-peptidyl polymer, depending on the change of the kind and amount of an alcohol (such as ethanol or isopropanol) and pH in a reaction medium; ii) reacting a physiologically active polypeptide with a non-peptidyl polymer (such as polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, PLA (poly(lactic acid)), PLGA (polylactic-glycolic acid), lipid polymers, chitins, hyaluronic acid, and combinations thereof) in a reaction medium having the kind and amount of an alcohol and the pH range determined in step i); and iii) isolating and purifying the physiologically active polypeptide conjugate from the reaction mixture of step (ii) by ion exchange chromatography using an alcohol.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式